TABLE 2

BMD Annual Growth Rate (g/cm² per year) by Corticosteroid Use and Smoking Status Stratified According to Gender

Variable at Last Follow-up Visit	Boys			Girls			P, Gender × Variable Interaction
Variable at Last Follow-up Visit	n	Rate^a	P	n	Rate^a	P	P, Gender × Variable Interaction
Cumulative OCS courses
0	108	0.052	Reference	66	0.052	Reference	Reference
>0 and <5	268	0.049	.1200	168	0.053	.7300	.0800
≥5	155	0.046	.0009	112	0.049	.2900	.0800
Test for trend			.0002			.2300	.1100
Cumulative ICS, mg
0	189	0.051	Reference	118	0.052	Reference	Reference
1–437	126	0.046	.0040	84	0.052	.9400	.0400
≥438^b	216	0.048	.0300	144	0.051	.5400	.5800
Test for trend			.0500			.4500	.6400
Passive smoking			.9100			.3500	.7500
No	318	0.049		178	0.051
Yes	213	0.049		168	0.052
Active smoking			.8100			.4200	.8900
No	503	0.049		320	0.051
Yes	28	0.050		26	0.054

↵a Adjusted for all variables in table; race and BMD at baseline; and the following variables with value at last follow-up visit: age, Tanner stage (genital stage for boys and breast stage for girls), machine type, fan-beam type, BMI-for-age percentile, and height. Rate was defined as (BMD at last follow-up − BMD at baseline visit)/years since baseline; BMD measurements were standardized to Hologic with fan beam by using the following formulas: Hologic BMD = 0.885*Lunar BMD; fan-beam BMD = pencil-beam BMD + .0549 if height ≥1.40 m.
↵b The amount of a full dose (400 μg/day) of budesonide in the CAMP trial for 3 years was 438 mg; patients in the 1- to 437-mg category had a median cumulative ICS amount of 153 mg, whereas patients in the ≥438-mg category had a median dose of 690 mg.